Machado, Marina Amaral de Ávila
de Moura, Cristiano Soares
Chan, Kelvin
Curtis, Jeffrey R.
Hudson, Marie
Abrahamowicz, Michal
Jamal, Rahima
Pilote, Louise
Bernatsky, Sasha
Article History
Received: 1 April 2020
Accepted: 22 July 2020
First Online: 3 September 2020
Competing interests
: M.H. has received unrestricted research funding from Roche and BMS for work related to immune related adverse events from immune checkpoint inhibitors. R.J. was an investigator on checkmate 067, the phase III trial evaluation the combination of ipilimumab and nivolumab. The remaining authors have no competing interests to declare.